Biotinylated Human EMMPRIN / CD147 Protein, Avitag™,His Tag
Proteins and Peptides
- 貨號 Cat. No.
- CD7-H82E0
- 規格 Size
- 200ug
- 品牌 Brand
- ACROBiosystems
- Species
- Human
- Conjugate
- Precision Avi
- Expression System
- HEK293
- Tag
- Avi Tag 、 His Tag
Description
Source :
Biotinylated Human EMMPRIN, Avitag,His Tag (CD7-H82E0) is expressed from human 293 cells (HEK293). It contains AA Ala 22 - His 205 (Accession # P35613-2).
Molecule : EMMPRIN
Synonyms : Basigin,BSG,5F7,CD147,EMMPRIN,M6,OK,TCSF
Format : Powder
Category : MABSol® Biotin Labeled Proteins
Accession : NP_940991.1
Storage : -20℃
Shipping condition : Powder,RT
Molecular Weight : 22.8 kDa
Characteristics :
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. The protein has a calculated MW of 22.8 kDa. The protein migrates as 30-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level : Less than 1.0 EU per μg by the LAL method.
Buffer : PBS, pH7.4
Description :
CD147 is also known as Basigin (BSG), or extracellular matrix metalloproteinase inducer (EMMPRIN). The human basigin protein contains 269 amino acids that form two heavily glycosylated C2 type immunoglobulin-like domains at the N-terminal extracellular portion. A second form of basigin has also been characterized that contains one additional immunoglobulin-like domain in its extracellular portion. As members of the immunoglobulin superfamily play fundamental roles in intercellular recognition involved in various immunologic phenomena, differentiation, and development, basigin is thought also to play a role in intercellular recognition and regulate several distinct functions, such as spermatogenesis, expression of the monocarboxylate transporter and the responsiveness of lymphocytes. Basigin is a type I integral membrane receptor that has many ligands, including the cyclophilin (CyP) proteins Cyp-A and CyP-B and certain integrins.
References :
(1) Kasinrerk W, , et al.,1992, J Immunol 149 (3): 847–54.
(2) Yurchenko V, et al., 2006, Immunology 117 (3): 301–9.
(3) Kanekura T, et al., 2002, Int. J. Cancer 99 (4): 520–8.
(4) Hakuma, N. et al., 2007, Oncology. 72 : 197-204.

